SciBase reaches milestone with over 300,000 patients tested with Nevisense

About Nevisense About Nevisense Designed to augment the capabilities of traditional dermoscopy,Nevisenseleverages the unique electrical properties of skin tissue to provide clinicians with objective data to support their clinical assessment. The device deliverspersonalized resultsthat help guide risk-aligned management strategies for patients with potentially malignant skin lesions. Withover 60 peer-reviewed clinical publicationsand studies, Nevisense has been shown to...

About Nevisense

Designed to augment the capabilities of traditional dermoscopy, Nevisense leverages the unique electrical properties of skin tissue to provide clinicians with objective data to support their clinical assessment. The device delivers personalized results that help guide risk-aligned management strategies for patients with potentially malignant skin lesions.

With over 60 peer-reviewed clinical publications and studies, Nevisense has been shown to improve diagnostic accuracy and support improved patient outcomes. Its non-invasive method enables more efficient biopsy management decisions while ensuring that high-risk cases receive timely attention.

As the global burden of melanoma continues to rise, technologies like Nevisense are proving invaluable in aiding early detection efforts-where outcomes are most favorable.

For additional information, please contact:
Pia Renaudin, CEO, tel. +46732069802, e-mail: [email protected]

Certified Advisor (CA): DNB Carnegie Investment Bank AB (publ) Phone: +46 (0)73 856 42 65 E-mail: [email protected]

About SciBase

SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops, manufactures, and commercializes Nevisense, a unique point-of-care platform that combines AI and advanced EIS technology to elevate diagnostic accuracy, ensuring proactive skin health management.

Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.

Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.

This information was brought to you by Cision http://news.cision.com.

https://news.cision.com/scibase/r/scibase-reaches-milestone-with-over-300-000-patients-tested-with-nevisense,c4155900

The following files are available for download:

 

View original content:https://www.prnewswire.co.uk/news-releases/scibase-reaches-milestone-with-over-300-000-patients-tested-with-nevisense-302465743.html